Prazosin, a centrally active alpha-1 adrenergic receptor antagonist, has reduced nightmares and sleep disturbances in placebo-controlled studies involving patients with combat and civilian related posttraumatic stress disorder (PTSD). In this retrospective chart review, we analyzed data from 23 refugees diagnosed with chronic PTSD who were treated with prazosin. The recurrent distressing dreams item of the Clinician Administered PTSD Scale (CAPS) was used to quantify nightmare severity. A Clinical Global Impressions-Change (CGI-C) score assessed change in overall PTSD severity exclusive of nightmares. Using a paired-samples t-test, we found that CAPS scores decreased significantly (p <0.0005) from baseline after 8 weeks of treatment with a stable dose of prazosin. Overall PTSD severity was "markedly improved" in 6 patients, "moderately improved" in 11 patients, and "minimally improved" in 6 patients. These data provide preliminary support for the use of prazosin in targeting reduction of trauma-related nightmares and promoting improvement of global clinical status within an international sample of severely traumatized refugee patients. Copyright © 2009 Lippincott Williams & Wilkins Inc.

Global concern Prazosin posttraumatic stress disorder Refugees nightmares

medical record review nightmare Clinical Global Impression scale refugee Student t test drug dose titration Prazosin Dreams human Refugees middle aged Aged Medical Audit dizziness statistical significance Young Adult Humans treatment duration male Adrenergic alpha-Antagonists dream female Psychiatric Status Rating Scales sertraline clinical article scoring system Article Retrospective Studies adult posttraumatic stress disorder data analysis Stress Disorders, Post-Traumatic drug dose increase disease severity retrospective study major depression bedtime dosage fluoxetine